9 insiders reported 46 Form 4 transactions for Olema Pharmaceuticals, Inc. (OLMA) over the past 18 months (most recent 2026-03-05). Recent activity: Mitchell Shawnte (CHIEF LEGAL OFFICER) Buy 15,000 shares, Mitchell Shawnte (CHIEF LEGAL OFFICER) Sell 15,000 shares, Mitchell Shawnte (CHIEF LEGAL OFFICER) Buy 25,000 shares, Mitchell Shawnte (CHIEF LEGAL OFFICER) Sell 24,767 shares, Mitchell Shawnte (CHIEF LEGAL OFFICER) Sell 233 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-05 | Mitchell Shawnte | CHIEF LEGAL OFFICER | Buy | 15,000 | $65,550 |
| 2026-03-05 | Mitchell Shawnte | CHIEF LEGAL OFFICER | Sell | 15,000 | $345,150 |
| 2026-03-05 | Mitchell Shawnte | CHIEF LEGAL OFFICER | Buy | 25,000 | $109,250 |
| 2026-03-05 | Mitchell Shawnte | CHIEF LEGAL OFFICER | Sell | 24,767 | $600,600 |
| 2026-03-05 | Mitchell Shawnte | CHIEF LEGAL OFFICER | Sell | 233 | $5,753 |
| 2026-02-17 | Austin Sasha Lu | VP of Finance and Controller | Buy | 11,700 | $0 |
| 2026-01-21 | Harmon Cyrus | Director | Sell | 10,000 | $268,800 |
| 2026-01-16 | Harmon Cyrus | Director | Sell | 3,489 | $101,600 |
| 2026-01-15 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Sell | 3,822 | $107,054 |
| 2026-01-15 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Sell | 100,000 | $2.9M |
| 2026-01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 49,800 | $1.4M |
| 2026-01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Buy | 50,000 | $243,500 |
| 2026-01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 10,000 | $283,400 |
| 2026-01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 200 | $5,698 |
| 2026-01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Buy | 50,000 | $243,500 |
| 2026-01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 14,997 | $428,914 |
| 2026-01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 35,003 | $1.0M |
| 2025-12-30 | Bohen Sean | President and CEO | Sell | 8,500 | $0 |
| 2025-12-29 | Harmon Cyrus | Director | Sell | 2,881 | $82,195 |
| 2025-12-23 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 1,225 | $34,398 |
| 2025-12-23 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 43,729 | $1.3M |
| 2025-12-23 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 6,046 | $189,784 |
| 2025-12-23 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 9,000 | $0 |
| 2025-12-23 | CLARK IAN T | Director | Buy | 209,690 | $924,733 |
| 2025-12-23 | CLARK IAN T | Director | Buy | 21,520 | $77,687 |
Source: SEC Form 4 filings · as of 2026-03-05